Chapter 3 The Genetic Basis and Molecular Pathogenesis of Huntington's Disease

Advances in Cell Aging and Gerontology

Volumn 3, Issue C, 1999, Pages 81-92

  Kowall, Neil W ^a   Kuemmerle, Stephan ^a   Ferrante, Robert J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0004876014     PISSN: 15663124     EISSN: None     Source Type: Book Series    
DOI: 10.1016/S1566-3124(08)60023-1     Document Type: Article

References (73)

1. Alford R.L., Ashizawa T., Jankovic J., Caskey C.T., and Richards C.S. Molecular detection of new mutations, resolution of ambiguous results and complex genetic counseling issues in Huntington disease. Am. J. Med. Genet. 66 (1996) 281-286
2. Andrew S.E., and Hayden M.R. Origins and evolution of Huntington disease chromosomes. Neurodegeneration 4 (1995) 239-244
3. Bateman D., Boughey A.M., Scaravilli E., Marsden C.D., and Harding A.E. A follow-up study of isolated cases of suspected Huntington's disease. Ann. Neurol. 31 (1992) 293-298
4. Beal M.F. Does impairment of energy metabolism result in excitotoxic neuronal death in neurodegenerative illnesses? Ann. Neurol. 31 (1992) 119-130
5. Beal M.F. Huntington's disease, energy, and excitotoxicity. Neurobiol. Aging 15 (1994) 275-276
6. Beal M.F., Matson W.R., Swartz K.J., Gamache P.H., and Bird E.D. Kynurenine pathway measurements in Huntington's disease striatum: evidence for reduced formation of kynurenic acid. J. Neurochem. 55 (1990) 1327-1339
7. Beal M.F., Swartz K.J., Ferrante R.J., and Kowall N.W. Chronic quinolinic acid lesions in rats closely resemble Huntington's disease. J. Neurosci. 11 (1991) 1649-1659
8. Beal M.F., Matson W.R., Storey E., Milbury P., Ryan E.A., Ogawa T., and Bird E.D. Kynurenic acid concentrations are reduced in Huntington's disease cerebral cortex [see comments]. Neurol. Sci. 108 (1992) 80-87
9. Bertaux F., Sharp A.H., Ross C.A., Lehrach H., Bates G.P., and Wanker E. HAP1-huntingtin interactions do not contribute to the molecular pathology in Huntington's disease transgenic mice. FEBS Lett. 426 (1998) 229-232
10. Blass J.P., Sheu R.K., and Cedarbaum J.M. Energy metabolism in disorders of the nervous system [review]. Rev. Neurol. 144 (1988) 543-563
11. Borlongan C.V., Koutouzis T.K., Randall T.S., Freeman T.B., Cahill D.W., and Sanberg P.R. Systemic 3-nitropropionic acid: behavioral deficits and striatal damage in adult rats. Brain Res. Bull. 36 (1995) 549-556
12. Boutell J.M., Wood J.D., Harper P.S., and Jones A.L. Huntingtin interacts with cystathionine beta-synthase. Hum. Mol. Genet. 7 (1998) 371-378
13. Brennan W.A.J., Bird E.D., and Aprille J.R. Regional mitochondrial respiratory activity in Huntington's disease brain. J. Neurochem. 44 (1985) 1948-1950
14. Brooks B.P., and Fischbeck K.H. Spinal and bulbar muscular atrophy: a trinucleotide-repeat expansion neurodegenerative disease. Trends Neurosci. 18 (1995) 459-461
15. Brouillet E., Hyman B.T., Jenkins B.G., Henshaw D.R., Schulz J.B., Sodhi P., Rosen B.R., and Beal M.F. Systemic or local administration of azide produces striatal lesions by an energy impairment-induced excitotoxic mechanism. Exp. Neurol. 129 (1994) 175-182
16. Brouillet E., Hantraye P., Ferrante R.J., Dolan R., Leroy W.A., Kowall N.W., and Beal M.F. Chronic mitochondrial energy impairment produces selective striatal degeneration and abnormal choreiform movements in primates. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 7105-7109
17. Bruce-Keller A.J., Umberger G., McFall R., and Mattson M.P. Food restriction reduces brain damage and improves behavioral outcome following excitotoxic and metabolic insults. Ann. Neurol. 45 (1999) 8-15
18. Bruyn R.P., and Stoof J.C. The quinolinic acid hypothesis in Huntington's chorea. J. Neurol. Sci. 95 (1990) 29-38
19. Burke J.R., Enghild J.J., Martin M.E., Jou Y.-S., Myers R.M., Roses A.D., Vance J.M., and Strittmatter W.J. Huntingtin and DRPLA proteins selectively interact with the enzyme GADPH. Nat. Med. 2 (1996) 347-350
20. Cooper J.K., Schilling G., Peters M.F., Herring W.J., Sharp A.H., Kaminsky Z., Masone J., Khan F.A., Delanoy M., Borchelt D.R., Dawson V.L., Dawson T.M., and Ross C.A. Truncated N-terminal fragments of huntingtin with expanded glutamine repeats form nuclear and cytoplasmic aggregates in cell culture. Hum. Mol. Genet. 7 (1998) 791-800
21. Coyle J.T., and Schwarcz R. Lesions of striatal neurons with kainic acid provides an animal model for Huntington's chorea. Nature 263 (1976) 244-246
22. Davies S.W., Turmaine M., Cozens B.A., DiFiglia M., Sharp A.H., Ross C.A., Scherzinger E., Wanker E.E., Mangiarini L., and Bates G.P. Formation of neuronal intranuclear inclusions underlies the neurological dysfunction in mice transgenic for the HD mutation. Cell 90 (1997) 537-548
23. Davies S.W., Beardsall K., Turmaine M., DiFiglia M., Aronin N., and Bates G.P. Are neuronal intranuclear inclusions the common neuropathology of triplet-repeat disorders with polyglutamine-repeat expansions?. Lancet 351 (1998) 131-133
24. DiFiglia M., Sapp E., Chase K., Schwarz C., Meloni A., Young C., Martin E., Vonsattel J.P., Carraway R., Reeves S.A., et al. Huntingtin is a cytoplasmic protein associated with vesicles in human and rat brain neurons. Neuron 14 (1995) 1075-1081
25. DiFiglia M., Sapp E., Chase K.O., Davies S.W., Bates G.P., Vonsattel J.P., and Aronin N. Aggregation of huntingtin in neuronal intranuclear inclusions and dystrophic neurites in brain. Science 277 (1997) 1990-1993
26. Dragatsis I., and Zeitlin A. Mouse mutant embryos lacking huntingtin are rescued from lethality by wild-type extraembryonic tissues. Development 125 (1998) 1529-1539
27. Duyao M.P., Auerbach A.B., Ryan A., Persichetti R., Barnes G.T., McNeil S.M., Ge P., Vonsattel J.P., Gusella J.R., and Joyner A.L. Inactivation of the mouse Huntington's disease gene homolog Hdh. Science 269 (1995) 407-410
28. Ferrante R.J., Kowall N.W., and Richardson E.P. Patch-matrix distribution of cholecystokinin and cytochrome oxidase activity in normal and Huntington's disease striatum. Soc. Neurosci. Abs. 14 (1988) 1046
29. Ferrante R.J., Kowall N.W., Cipolloni P.B., Storey E., and Beal M.F. Excitotoxin lesions in primates as a model for Huntington's disease: histopathologic and neurochemical characterization. Exp. Neurol. 119 (1993) 46-71
30. Ferrante R.J., Gutekunst C.A., Persichetti R., McNeil S.M., Kowall N.W., Gusella J.R., MacDonald M.E., Beal M.F., and Hersch S.M. Heterogeneous topographic and cellular distribution of huntingtin expression in the normal human neostriatum. J. Neurosci. 17 (1997) 3052-3063
31. Ferrante R.J., Shulz J.B., Kowall N.W., and Beal M.F. Systemic administration of rotenone produces selective damage in the striatum and globus pallidus, but not the substsantia nigra. Brain Res. 753 (1997) 157-162
32. Finch C.E., and Morgan T.E. Food restriction and brain aging. Adv. Cell Aging Gerontol. 2 (1997) 279-297
33. Gentile V., Sepe C., Calvani M., Melone M.A., Cotrufo R., Cooper A.J., Blass J.P., and Peluso G. Tissue transglutaminase-catalyzed formation of high-molecular-weight aggregates in vitro is favored with long polyglutamine domains: a possible mechanism contributing to CAG-triplet diseases. Arch. Biochem. Biophys. 352 (1998) 314-321
34. Gourfinkel-An I., Cancel G., Trottier Y., Devys D., Tora L., Lutz Y., Imbert G., Saudou R., Stevanin G., Agid Y., Brice A., Mandel J.L., and Hirsch E.C. Differential distribution of the normal and mutated forms of huntingtin in the human brain. Ann. Neurol. 42 (1997) 712-719
35. Gu M., Gash M.T., Mann V.M., Javoy A.R., Cooper J.M., and Schapira A.H. Mitochondrial defect in Huntington's disease caudate nucleus. Ann. Neurol. 39 (1996) 385-389
36. Gusella J.F., and MacDonald M.E. Huntington's disease [review], Sem. Cell Biol. 6 (1995) 21-28
37. Gutekunst C.A., Levey A.I., Heilman C.J., Whaley W.L., Yi H., Nash N.R., Rees H.D., Madden J.J., and Hersch S.M. Identification and localization of huntingtin in brain and human lymphoblastoid cell lines with anti-fusion protein antibodies. Proc. Natl. Acad. Sci. U. S. A. 92 (1995) 8710-8714
38. Hackam A.S., Singaraja R., Wellington C.L., Metzler M., McCutcheon K., Zhang T., Kalchman M., and Hayden M.R. The influence of huntingtin protein size on nuclear localization and cellular toxicity. J. Cell Biol. 141 (1998) 1097-1105
39. Hatefi Y. The mitochondrial electron transport and oxidative phosphorylation system. Annu. Rev. Biochem. 54 (1985) 1015-1069
40. Holmberg M., Duyckaerts C., Durr A., Cancel G., Gourfinkel-An I., Damier P., Faucheux B., Trottier Y., Hirsch E.C., Agid Y., and Brice A. Spinocerebellar ataxia type 7 (SCA7): a neurodegenerative disorder with neuronal intranuclear inclusions. Hum. Mol. Genet. 7 (1998) 913-918
41. Homberg V., and Huttunen J. Muscle tone in Huntington's disease. J. Neurol. Sci. 121 (1994) 147-154
42. Hoogeveen A.T., Willemsen R., Meyer N., de Rooij K.E., Roos R.A., Van Ommen O.G., and Galjaard H. Characterization and localization of the Huntington disease gene product. Hum. Mol. Genet. 2 (1993) 2069-2073
43. Huntington's Disease Collaborative Research Group. A novel gene containing a trinucleotide repeat that is expanded and unstable on Huntington's disease chromosomes. Cell 72 (1993) 971-983
44. Jenkins B.G., Koroshetz W.J., Beal M.F., and Rosen B.R. Evidence for impairment of energy metabolism in vivo in Huntington's disease using localized 1H NMR spectroscopy. Neurology 43 (1993) 2689-2695
45. Kalchman M.A., Koide H.B., McCutcheon K., Graham R.K., Nichol K., Nishiyama K., Kazemi-Esfarjani P., Lynn F.C., Wellington C., Metzler M., Goldberg Y.P., Kanazawa I., Gietz R.D., and Hayden M.R. HIP1, a human homologue of S. cerevisiae S1a2p, interacts with membrane-associated huntingtin in the brain. Nat. Genet. 16 (1997) 44-53
46. Kang S., Ohshima K., Shimizu M., Amirhaeri S., and Wells R.D. Pausing of DNA synthesis in vitro at specific loci in CTG and CGG triplet repeats from human hereditary disease genes. J. Biol. Chem. 270 (1995) 27014-27021
47. Kosinski C.M., Cha J.H., Young A.B., Persichetti E., MacDonald M., Gusella J.F., Penney Jr. J.B., and Standaert D.G. Huntingtin immunoreactivity in the rat neostriatum: differential accumulation in projection and interneurons. Exp. Neurol. 144 (1997) 239-247
48. Kowall N.W., Ferrante R.J., and Martin J.B. Patterns of cell loss in Huntington's disease. TINS 10 (1987) 24-29
49. La Spada A.R., Paulson H.L., and Fischbeck K.H. Trinucleotide repeat expansion in neurological disease. Ann. Neurol. 36 (1994) 814-822
50. Larsson N.-G., Andersen O., Home E., Oldfors A., and Wahlstrom J. Leber's hereditary optic neuropathy and Complex I deficiency in muscle. Ann. Neurol 30 (1991) 701-708
51. Lesort M., Attanavanich K., Zhang J., and Johnson G.V. Distinct nuclear localization and activity of tissue transglutaminase. J. Biol. Chem. 273 (1998) 11991-11994
52. Li X.J., Li S.H., Sharp A.H., Nucifora Jr. F.C., Schilling G., Lanahan A., Worley P., Snyder S.H., and Ross C.A. A huntingtin-associated protein enriched in brain with implications for pathology. Nature 378 (1995) 398-402
53. Linnane A.W., Marzuki S., Ozawa T., and Tanaka M. Mitochondrial DNA mutations as an important contributor to ageing and degenerative diseases. Lancet 1 (1989) 642-645
54. Mann V.M., Cooper J.M., Javoy-Agid F., Agid F., Jenner P., and Schapira A.H.V. Mitochondrial function and parental sex effect in Huntington's disease. Lancet 336 (1990) 749
55. Martindale D., Hackam A., Wieczorek A., Ellerby L., Wellington C., McCutcheon K., Singaraja R., Kazemi-Esfarjani P., Devon R., Kim S.U., Bredesen D.E., Tufaro F., and Hayden M.R. Length of huntingtin and its polyglutamine tract influences localization and frequency of intracellular aggregates. Nat. Genet. 18 (1998) 150-154
56. McGeer E.G., and McGeer P.L. Duplication of biochemical changes of Huntington's chorea by intrastriatal injections of glutamic and kainic acid. Nature 263 (1976) 517-519
57. Nakayabu M., Miwa S., Suzuki M., Izuta S., Sobue G., and Yoshida S. Mismatched nucleotides may facilitate expansion of trinucleotide repeats in genetic diseases. Nucleic Acids Res. 26 (1998) 1980-1984
58. Parker W.D.J., Boyson S.J., Luder A.S., and Parks J.K. Evidence for a defect in NADH: ubiquinone oxidoreductase (complex I) in Huntington's diseases. Neurology 40 (1990) 1231-1234
59. Pearson S.J., and Reynolds G.P. Increased brain concentrations of a neurotoxin, 3-hydroxykynurenine, in Huntington's disease. Neurosci. Lett. 144 (1992) 199-201
60. Plassart E., and Fontaine B. Genes with triplet repeats: a new class of mutations causing neurological diseases. Biomed. Pharmacother. 48 (1994) 191-197
61. Ross C.A. Intranuclear neuronal inclusions: a common pathogenic mechanism for glutamine-repeat neurodegenerative diseases?. Neuron 19 (1997) 1147-1150
62. Schulz J., Henshaw D., Siwek D., MacGarvey U., Jenkins B., Ferrante R., Cipolloni P., Kowall N., Rosen B., and Beal M. Involvement of free radicals in excitotoxicity in vivo. Neurochem 64 (1995) 2239-2247
63. Sharp A.H., Loev S.J., Schilling G., Li S.H., Li X.J., Bao J., Wagster M.V., Kotzuk J.A., Steiner J.P., Lo A., et al. Widespread expression of Huntington's disease gene (IT15) protein product. Neuron 14 (1995) 1065-1074
64. Singhrao S.K., Thomas P., Wood J.D., MacMillan J.C., Neal J.W., Harper P.S., and Jones A.L. Huntingtin protein colocalizes with lesions of neurodegenerative diseases: an investigation in Huntington's, Alzheimer's, and Pick's diseases. Exp. Neurol. 150 (1998) 213-222
65. Tatter S.B., Galpern W.R., Hoogeveen A.T., and Isacson O. Effects of striatal excitotoxicity on huntingtin-like immunoreactivity. Neuroreport 6 (1995) 1125-1129
66. Tellez-Nagel I., Johnson A.B., and Terry R.D. Ultrastructural and histochemical study of cerebral biopsies in Huntington's chorea. Adv. Neurol. 1 (1973) 387-398
67. Thompson P.D., Berardelli A., Rothwell J.C., Day B.L., Dick J.P., Benecke R., and Marsden C.D. The coexistence of bradykinesia and chorea in Huntington's disease and its implications for theories of basal ganglia control of movement. Brain 111 (1988) 223-244
68. Trottier Y., Devysm D., Imbert G., Saudou R., An I., Lutz Y., Weber C., Agid Y., Hirsch E.C., and Mandel J.L. Cellular localization of the Huntington's disease protein and discrimination of the normal and mutated form. Nat. Genet. 10 (1995) 104-110
69. Trounce I., Byrne E., and Marzuki S. Decline in skeletal muscle mitochondrial respiratory chain function: possible factor in ageing. Lancet 1 8639 (1989) 637-639
70. Tukamoto T., Nukina N., Ide K., and Kanazawa I. Huntington's disease gene product, huntingtin, associates with microtubules in vitro. Arch. Med. Res. 28 (1997) 513-516
71. Wallace D.C. Mitochondrial genes and neuromuscular disease. Res. Publ. Assoc. Res. Nerv. Ment. Dis. 69 (1991) 101-120
72. Wellington C.L., Ellerby L.M., Hackam A.S., Margolis R.L., Trifiro M.A., Singaraja R., McCutcheon K., Salvesen G.S., Propp S.S., Bromm M., Rowland K.J., Zhang T., Rasper D., Roy S., Thornberry N., Pinsky L., Kakizuka A., Ross C.A., Nicholson D.W., Bredesen D.E., and Hayden M.R. Caspase cleavage of gene products associated with triplet expansion disorders generates truncated fragments containing the polyglutamine tract. J. Biol. Chem. 273 (1998) 9158-9167
73. Zeitlin S., Liu J.P., Chapman D.L., Papaioannou V.E., and Efstratiadis A. Increased apoptosis and early embryonic lethality in mice nullizygous for the Huntington's disease gene homologue. Nat. Genet. 11 (1995) 155-163